The Significance of Age and Causative Bacterial Morphology in the Choice of an Antimicrobial Agent to Treat Acute Uncomplicated Cystitis by Uehara, Shinya et al.
A bout half of all women experience a urinary tract infection (UTI) sometime in their lives,  and a 
quarter of women contract a UTI multiple times [1].  
Most UTIs in young women are acute uncomplicated 
cystitis [2].  The issue of acute uncomplicated cystitis 
being resistant to antibiotics has been widely raised 
recently [3],  with resistance to quinolone antibiotics 
being especially noticeable [4-6].  There is also a rise in 
extended-spectrum beta-lactamase (ESBL)-producing 
bacteria.  These trends mean that appropriate drug choice 
is more vital now than ever.
The causative bacteria in acute uncomplicated cysti-
tis have been shown to differ between pre- and post-
menopausal females.  Specifically,  the ratio of Gram-
positive cocci (GPC) to Gram-negative rod (GNR) 
bacteria declines in postmenopausal cases,  and the 
percentages of quinolone-resistant bacteria and ESBL-
producing bacteria tend to increase.  Therefore,  the 
drug susceptibility of pre- and postmenopausal patients 
is considered to be different [3].  Another tendency is 
that antibacterial agents are less effective for short-term 
treatment in postmenopausal women than in premeno-
pausal women [7].  In addition,  it is reasonable to diag-
nose acute uncomplicated cystitis in patients younger 
than 40 years of age based on the results of a urine test,  
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Differentiating patients by age and causative bacterial morphology might aid in making the appropriate choice 
of antimicrobial agent when treating acute uncomplicated cystitis.  In this retrospective analysis,  the non-sus-
ceptibility rates of the causative bacteria to cefcapene-pivoxil (CFPN-PI) and levofloxacin (LVFX) were deter-
mined after dividing patients with acute uncomplicated cystitis by age group (15-54 and 55-74 years old) and by 
bacterial morphology: gram-positive cocci (GPC) or gram-negative rod (GNR).  The overall non-susceptibility 
rates for CFPN-PI and LVFX were 19.4% and 15.3%,  respectively.  When the subjects were divided by age,  only 
the non-susceptibility rate for LVFX in the younger group significantly decreased (to 8.7%).  When the groups 
were divided by both age and bacterial morphology,  the younger GNR group had non-susceptibility rates of 
6.9% to CFPN-PI and 7.8% to LVFX,  whereas the younger GPC group showed 10.2% non-susceptibility to 
LVFX.  The older GNR group showed 9.8% non-susceptibility to CFPN-PI,  while the older GPC group showed 
7.2% non-susceptibility to LVFX.  All the non-susceptibility rates were lower than 10.2% in the sub-divided 
groups.  Differentiating patients by age and the morphology of causative bacteria can aid in making the appro-
priate choice of antimicrobial agent and may improve treatment outcomes in patients with acute uncomplicated 
cystitis.
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a urine culture and symptoms.  However,  for patients 
over 40,  the underlying conditions of the UTI need to 
be differentiated when making a diagnosis [8 , 9].
According to the Japanese Association for Infectious 
Diseases/Japanese Society of Chemotherapy (JAID/JSC) 
Guidelines for Clinical Management of Infectious 
Diseases 2015 (2015 Guidelines) [10],  the first-line 
agent for treating acute uncomplicated cystitis in pre-
menopausal patients is quinolone antibiotics,  whereas 
the first choice for postmenopausal patients is either 
cephem antibiotics or penicillin combined with a 
beta-lactamase inhibitor.  The 2015 Guidelines marked 
a change from previous editions,  which always recom-
mended quinolone antibiotics as the first choice,  with 
no consideration of menopausal status.  The 2015 
Guidelines do,  however,  state that the causative bacte-
rial morphology should be classified as GNR or GPC 
before the administration of any antimicrobial agent,  
and they stress the importance of choosing the most 
appropriate antimicrobial agent [10].
This study divided patients by age and bacterial 
morphology in order to examine their susceptibility to 
various antimicrobial agents with the aim of obtaining 
useful data to guide the choice of antimicrobial agent 
when treating acute uncomplicated cystitis.
Research Material and Methods
Subjects. The subjects for this retrospective study 
were 935 women clinically diagnosed with acute 
uncomplicated cystitis at the Department of Urology in 
Abiko Toho Hospital between January 1st,  2012 and 
December 31st,  2018.  Acute cystitis was diagnosed in 
cases with clinical symptoms,  pyuria and bacteriuria.  
Pyuria was defined as the presence of a urine sediment 
specimen with at least 5 white blood cells (WBCs) per 
high-power field.  Bacteriuria was defined as a viable 
bacterial count equivalent to or greater than 104 CFU/ml 
in the midstream urine.  An ultrasound test was done to 
exclude complicated UTI.  Patients younger than 15 and 
older than 75 years of age were excluded due to the pos-
sibility of having potential underlying conditions in the 
urinary tract.
Methods. Urine samples were incubated at 37°C 
for 24 h,  and the bacterial counts and strains were 
identified.  Drug susceptibility testing was performed 
using a broth microdilution method,  and the drug sus-
ceptibility was categorized as “susceptible” (S),  “inter-
mediate” (I) or “resistant” (R),  with I and R considered 
to be non-susceptible to the tested drug according to the 
breakpoints recommended by the Clinical and 
Laboratory Standards Institute in document M100-S17 
[11].  If the minimum concentration of ceftazidime 
needed to inhibit Enterobacteriaceae was more than 
2 μg/ml,  the presence of ESBL-producing bacteria was 
suspected,  and a double-disk synergy test was added to 
confirm the presence of ESBL.
The susceptibility of bacteria to the oral cephem 
agent cefcapene-pivoxil (CFPN-Pl) and the quinolone 
agent levofloxacin (LVFX) was examined.  Amoxicillin 
(AMPC),  minocycline (MINO),  cefotiam (CTM),  cef-
triaxone (CTRX),  tazobactam/piperacillin (TAZ/PIPC),  
and meropenem (MEPM) were also tested.
The patients were divided by age into 10-year groups 
from 15 to 74.  Next,  to determine an approximate cut-
off for dividing the cases into pre- and postmenopausal 
groups,  the GNR/GPC ratio,  the percentage of ESBL-
producing bacteria and the non-susceptibility to LVFX 
were determined for each age group.  Using that data,  
the patients were divided into just 2 age groups,  15-54 
and 55-74 years old.  For both age groups,  the follow-
ing data were gathered: the non-susceptibility rate for 
each drug for each age and GNR/GCP status group,  and 
the percentage of ESBL-producing bacteria.
Statistical analysis. The median value (inter-
quartile range) of the results of each test was used as a 
continuous variable,  and n (%) was used as a categori-
cal variable.  A chi-squared test was used to compare the 
categorical variables,  with significance at p < 0.05.  EZR 
(Saitama Medical Center,  Jichi Medical University,  
Saitama,  Japan) statistical software was used to conduct 
the analysis.
Ethical considerations. This study was examined 
and approved by the Ethics Committee at Abiko Toho 
Hospital (approval number: 201918).
Results
The final number of subjects was 935.  Their median 
age was 58 years old (interquartile range: 43-67 years 
old).  The distribution of the causative bacteria is shown 
in Fig. 1; 82.1% of the isolates were GNR bacteria and 
17.9% were GPC bacteria.  Bacterial classification found 
67.0% Escherichia coli (E.coli),  followed by 11.4% 
Enterococcus,  5.7% Klebsiella pneumonia,  and 3.7% 
Streptococcus.  Table 1 shows the non-susceptibility rates 
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of all of the bacteria collectively and that of E. coli spe-
cifically,  since it accounted for over two-thirds of the 
cases.  Overall,  the non-susceptibility rates were 19.4% 
for CFPN-PI and 15.3% for LVFX,  showing little differ-
ence between the 2 agents.  The injectable cephem anti-
biotics CTM,  CTRX,  TAZ/PIPC and MEPM had 
non-susceptibility rates of 20.0%,  16.1%,  1.7% and 
2.2%,  respectively.  The non-susceptibility rates of 
CFPN-PI and LVFX in just the E. coli portion of the cases 
were 8.8% and 20.1%,  respectively,  indicating that 
quinolone antibiotics had a higher non-susceptibility 
rate than cephem antibiotics.  The non-susceptibility 
rates of injectable CTM,  CTRX,  TAZ/PIPC or MEPM 
in just the E. coli portion of cases were 6.1%,  5.3%,  0.6% 
and 0%,  respectively.
The patients were divided by age into 10-year groups 
from 15 to 74,  and the following data were com-
piled: the ratio of GPC to GNR cases,  the rates of 
non-susceptibility to LVFX,  and the percentage of cases 
with ESBL-producing bacteria (Fig. 2).  The ratio of 
GPC occurrence tended to decrease with age,  while 
non-susceptibility to LVFX and the percentage of cases 
with ESBL-producing bacteria rose in patients over 
55 years old.  Based on these findings,  the patients were 
subsequently divided into two age groups of 15-54 and 
55-74 years old.
The relationship between age and GPC/GNR 
classification was examined (Table 2).  The younger,  
15-54 year-old group had 76.6% GNR and 23.4% GPC 
bacteria.  The older,  55-74 year-old group had 86.6% 
GNR and 13.4% GPC bacteria.  The older group had a 
significantly higher GNR isolation rate (p < 0.001).
Next,  the relationship between age and oral antibi-
otic resistance was examined (Table 3).  The rates of 
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Table 1　 Antibiotic non-susceptibility rate
antimicrobials Overall (%) (n=935)












Table 2　 GNR/GPC distribution by age group
GNR GPC
15-54 (y.o.) 76.6 23.4
55-74 (y.o.) 86.6 13.4(%)
Table 3　 Non-susceptibility rates by age group
















Fig. 1　 Isolates of acute uncomplicated cystitis.  A,  Classification 












15-24 25-34 35-44 45-54 55-64 65-74
GPC GNR LVFX non-susceptibility rate
A
B age 15-24 25-34 35-44 45-54 55-64 65-74
number 51 72 143 153 216 300
ESBL producing bacteria (%) 0 2.8 2.8 2.6 6.0 4.3
Fig. 2　 GNR/GPC distribution,  LVFX non-susceptibility and 
ESBL-producing bacteria by age group.  A,  GNR/GPC distribution 
and the rate of non-susceptibility to LVFX by age group; B,  
Percentage of ESBL-producing bacteria by age
non-susceptibility to AMPC,  CFPN-PI and LVFX in the 
younger group were 32.2%,  20.0% and 8.4%,  respec-
tively,  with the older group showing 41.7%,  18.2% and 
20.9% rates of non-susceptibility,  respectively.  The 
non-susceptibility rate of LVFX in the younger group 
was significantly lower than that in the overall group 
(p < 0.001),  while the rates for AMPC and CFPN-PI 
were not improved in the younger group compared to 
the overall group.  In the older group,  the non-suscep-
tibility rates to AMPC,  LVFX,  and CFPN-PI did not 
decrease in comparison to the overall group.
The percentage of cases with ESBL-producing bacte-
ria was also examined by age group.  Overall,  2.4% of 
the younger group and 5.0% of the older group had 
ESBL-producing bacteria.  When only E. coli cases were 
examined,  3.4% of the younger group and 7.2% of the 
older group had ESBL-producing bacteria.  The older 
group had a higher percentage of ESBL-producing bac-
teria,  but the difference was not statistically significant 
(overall: p = 0.054; E.coli: p = 0.052).
The patients were divided into 4 groups by age group 
and GNR/GPC status to examine the drug non-suscep-
tibility rates (Table 4).  The younger GNR group had a 
non-susceptibility rate of 6.9% to CFPN-PI and 7.8% to 
LVFX,  whereas in the younger GPC group the 
non-susceptibility rate to LVFX was 10.2%.  The older 
GNR group had a non-susceptibility rate of 9.8% to 
CFPN-PI,  and in the older GPC group the rates were 
1.4% to AMPC and 7.2% to LVFX.  By dividing the sub-
jects into sub-groups and choosing the appropriate 
antibiotic for each group,  the non-susceptibility rates 
declined to 10.2% or lower.
Table 4 clearly shows that,  in younger patients,  
either cephem or quinolone antibiotics should be cho-
sen to treat GNR bacteria,  and only quinolone antibiot-
ics should be chosen to treat GPC bacteria.  In older 
patients,  cephem antibiotics should be used to treat 
GNR bacteria and penicillin or quinolone antibiotics 
should be used to treat GPC bacteria.
Discussion
When determining which antimicrobial agent to use 
to treat acute uncomplicated cystitis,  the JAID/JSC 
2015 Guidelines state that for premenopausal patients,  
quinolone antibiotics are the first-line agent and are also 
recommended for premenopausal patients with GPC 
bacteria.  For postmenopausal patients,  the first choice 
is either cephem antibiotics or penicillin with a 
beta-lactamase inhibitor,  and quinolone antibiotics are 
a second choice,  but should be chosen when the patient 
has GPC bacteria [10].  The Guidelines emphasize that 
quinolone antibiotics should not be chosen uncondi-
tionally,  and that the bacteria should be classified by 
Gram staining before any antibiotic is chosen.
This retrospective study reviewed a large number of 
cases from general clinical practices and examined how 
classifying patients by age and bacterial morphology 
might help with selecting the appropriate antimicrobial 
agent.  When the patients were divided into two age 
groups (15-54 and 55-74 years-old),  only the non-sus-
ceptibility to quinolone antibiotics in the younger group 
improved significantly compared to overall non-sus-
ceptibility.  The older group showed no significant dif-
ference in susceptibility compared to the overall rates.  
However,  when the subjects were divided more pre-
cisely by age,  GPC/GNR morphology and drug,  the 
non-susceptibility rates fell to 10.2% or lower for LVFX 
when treating GPC bacteria in the younger group,  for 
both LVFX and CFPN-PI in the younger GNR group,  
for AMPC and LVFX in the older GPC group,  and for 
CFPN-PI in the older GNR group.  Dividing patients 
not only by age but also by Gram-staining to determine 
the bacterial morphology in detail can determine the 
appropriate choice of antimicrobial agent.  This detailed 
division of cases shows the potential of directed therapy 
to improve treatment decisions and also reinforces the 
validity of the 2015 Guidelines.
The overall distribution of bacteria was 82.1% GNR 
and 17.9% GPC,  with 67.0% of the overall bacteria 
identified as E. coli.  This distribution closely matched 
the distribution results previously reported in Japan 
[3 , 12 , 13],  so this study’s cohort can be considered to 
be a similarly representative sample.  The overall 
non-susceptibility rates were 20% to oral cephem anti-
biotics and 15% to quinolone antibiotics,  which were 
equivalent to the findings of previous reports [7 , 13].  
Taking these findings together,  the efficacy of oral 
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Table 4　 Non-susceptibility rates by age group and GNR/GPC 
status
15-54 (y.o.) 55-74 (y.o.)
GNR GPC GNR GPC
AMPC 38.0 13.3 47.9  1.4
CFPN-PI  6.9 63.3  9.8 76.8
LVFX  7.8 10.2 23.0  7.2 (%)
cephem antibiotics can theoretically be considered to be 
80% and that of quinolone antibiotics to be 85%.  E. coli 
showed non-susceptibility rates in this study of roughly 
9% to oral cephem agents and about 20% to quinolone 
agents,  results that were equivalent to those in another 
published report [3].  Matsumoto et al.  [14] reported on 
drug susceptibility in the treatment of acute uncompli-
cated cystitis.  Their patients were divided into pre- and 
postmenopausal groups,  with postmenopausal patients 
having about a 5% higher non-susceptibility rate to both 
cephem and quinolone antibiotics.  Koguchi et al.  [13] 
conducted a similar examination in which the cohort 
was divided at the age of 50,  and although the results 
were not significant,  the rate of non-susceptibility to 
quinolone antibiotics was 5% lower among patients 
under 50 years old.
The 2015 Guidelines state that antimicrobial agents 
should be chosen based on menopause status,  but there 
are no detailed guidelines regarding age.  To determine 
the specific age groups used in this study,  the patients 
were first divided by age into 10-year groups from 15 to 
74.  Then,  the distribution of the causative bacteria,  the 
rate of non-susceptibility to LVFX and the percentage of 
cases with ESBL-producing bacteria were established.  
From the age of 55,  there was a decrease in the ratio of 
GPC cases,  as well as increases in LVFX non-suscepti-
bility and the percentage of ESBL-producing bacteria.  
Studies on age at menopause in Japan indicated that 
50% of women aged 50.54 years old were in menopause 
and 90% of women aged 56.34 years old were in meno-
pause [15 , 16].  Thus,  it is reasonable to define post-
menopausal as 55 years old and older.  Accordingly,  in 
this study we divided the cases into two age groups,  
15-54 and 55-74 years old.
The younger group was ≈ 20% non-susceptible to oral 
cephem antibiotics and ≈ 9% non-susceptible to quino-
lone antibiotics.  The older group was ≈ 18% non-sus-
ceptible to oral cephem antibiotics and ≈ 21% non-sus-
ceptible to quinolone antibiotics.  The younger group 
had a lower non-susceptibility to quinolone antibiotics 
than the overall cohort.  However,  dividing the subjects 
by age did not show any improvement in non-suscepti-
bility to cephem antibiotics in the younger group,  nor 
to either antibiotic category in the older group.  These 
tendencies were similarly reported by Koguchi et al.  
[13],  whose study divided the patients at age 50.  The 
fact that the younger group had a higher ratio of GPC 
cases is considered to be related to the improvement of 
the rate of non-susceptibility to quinolone antibiotics in 
that group as well as the non-improvement of the rate of 
non-susceptibility to cephem antibiotics.  Because the 
ratio of GNR bacteria in the older group was higher,  the 
rate of non-susceptibility to cephem antibiotics was 
expected to go down,  but no trend of improvement was 
seen,  possibly due to the higher prevalence of ESBL-
producing bacteria in the older group.
The percentage of ESBL-producing bacteria 
increased to 5.0% in the older group,  indicating that the 
presence of ESBL-producing bacteria greatly affects the 
rate of non-susceptibility to cephem antibiotics in GNR 
bacteria.  Heytens et al.  [17] found that ESBL-producing 
bacteria accounted for 2.5% of all E. coli,  and that ESBL-
producing bacteria were present in 1.7% of patients 
18-55 years old and 5.8% of those ≥ 56 years old.  Our 
study detected ESBL-producing bacteria in 7.2% of the 
older group,  and this is considered to have affected the 
decrease in drug susceptibility.
When we divided subjects by both age and GNR/
GPC status,  the younger GNR group was ≈ 7-8% 
non-susceptible to both cephem and quinolone antibi-
otics,  and the younger GPC group was ≈ 10% non-sus-
ceptible to quinolone antibiotics.  The older GNR group 
had a non-susceptibility rate of ≈ 10% to cephem antibi-
otics,  and the older GPC group was ≈ 7% non-suscepti-
ble to quinolone antibiotics and ≈ 2% to penicillin.  
Thus,  the non-susceptibilities had improved to ≈ 10% or 
lower.  Therefore,  for younger premenopausal patients 
with GNR bacteria,  either cephem or quinolone antibi-
otics can be chosen,  and when premenopausal patients 
have GPC bacteria,  quinolone antibiotics should be 
chosen.  For postmenopausal patients,  cephem antibi-
otics should be chosen to treat GNR bacteria,  and 
quinolone or penicillin antibiotics should be chosen 
when GPC bacteria are present.  Choosing the appro-
priate antibiotic can improve the treatment efficacy to 
over 90% in some instances.  The importance of differ-
entiating patients by both age and bacterial morphol-
ogy,  especially for older postmenopausal patients,  has 
been clearly shown.
This study did not examine penicillin with a beta- 
lactamase inhibitor,  did not evaluate clinical outcomes,  
and did not evaluate how ESBL-producing bacteria were 
treated.  Although there are some issues to be resolved,  
differentiating patients by age and causative bacteria 
morphology can help determine the treatment choice 
for acute uncomplicated cystitis.
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Considering the collateral damage caused by quino-
lone-resistant GNR bacteria,  always choosing quino-
lone antibiotics as the first-line treatment should be 
avoided [10].  If antimicrobial agents are chosen in the 
way indicated in this study,  and cephem antibiotics and 
even penicillin with a beta-lactamase inhibitor are 
appropriately used,  overall drug effectiveness can be 
improved while simultaneously decreasing the amount 
of quinolone agents used.
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